Potential market for novel tuberculosis diagnostics: Worth the investment?

Journal of Infectious Diseases

Volumn 211, Issue , 2015, Pages S58-S66

  Kik, Sandra V ^a   Denkinger, Claudia M ^a,b   Jefferson, Carole ^c   Ginnard, Janet ^d   Pai, Madhukar ^a  

^a MCGILL UNIVERSITY   (Canada)

^b FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

^c Independent Consultant   (United States)

^d UNITAID   (Switzerland)

Author keywords

Cost; Diagnostics; Market analysis; Market projection; Target product profiles; Tests; Tuberculosis

Indexed keywords

BIOLOGICAL MARKER;

ANTIBIOTIC SENSITIVITY; ARTICLE; BRAZIL; CHINA; COST; DIAGNOSTIC TEST; DRUG RAPID TEST; HUMAN; INDIA; PRIORITY JOURNAL; SOUTH AFRICA; SPUTUM SMEAR; TUBERCULOSIS; ECONOMICS; HEALTH CARE COST; MEDICAL RESEARCH; MOLECULAR DIAGNOSIS; PROCEDURES; TRENDS;

BIOMEDICAL RESEARCH; BRAZIL; CHINA; DIAGNOSTIC TESTS, ROUTINE; HEALTH CARE SECTOR; HUMANS; INDIA; MOLECULAR DIAGNOSTIC TECHNIQUES; SOUTH AFRICA; TUBERCULOSIS;

EID: 84930001274     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu817     Document Type: Article

References (16)

1. World Health Organization. WHA approves Post-2015 Global TB Strategy and Targets. Geneva 19 May 2014. http://who.int/tb/features-archive/globaltb-strategy/en/. Accessed 20 October 2014.
2. Dowdy DW, Houben R, Cohen T, et al. Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling. Int J Tuberc Lung Dis 2014;18:1012-8.
3. Kik SV, Denkinger CM, Casenghi M, Vadnais C, Pai M. Tuberculosis diagnostics: which target product profiles should be prioritised? Eur Respir J 2014;44:537-40.
4. Denkinger CM, Kik SV, Cirillo DM, et al. Defining the needs for next generation assays for tuberculosis. J Infect Dis 2015;211(suppl 2):S29-38.
5. World Health Organization. Meeting report. High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. 28-29 April 2014. Geneva, Switzerland, 2014. http://apps.who.int/iris/bitstream/10665/135617/1/WHO-HTM-TB-2014.18-eng.pdf?ua=1. Accessed 24 October 2014.
6. Pai M. Diagnostics for tuberculosis: what test developers want to know. Expert Rev Mol Diagn 2013;13:311-4.
7. TB Diagnostics Market Analysis Consortium. Market assessment of tuberculosis diagnostics in Brazil in 2012. PloS One 2014;9:e104105.
8. Special Programme for Research & Training in Tropical Diseases (TDR) and Foundation for Innovative New Diagnostics (FIND). Diagnostics for tuberculosis. Global demand and market potential. Geneva: World Health Organization, 2006:1-203.
9. TB Diagnostics Market Analysis Consortium. Market Assessment of Tuberculosis Diagnostics in South Africa in 2012-2013. Int J Tuberc Lung Dis 2015;19(2):216-22.
10. Pantoja A, Kik SV, Denkinger CM. Costs of novel TB diagnostics-will countries be able to afford it? J Infect Dis 2015;211(suppl 2):S67-77.
11. World Health Organization. Global Tuberculosis Report 2013: WHO report 2013. Geneva: WHO, 2013:1-289.
12. Worldbank. Data from database: Health Nutrition and Population Statistics: Population estimates and projections. http://data.worldbank.org/indicator/SP. POP. TOTL. Accessed 26 September 2014.
13. van't Hoog AH, Cobelens F, Vassall A, et al. Optimal triage test characteristics to improve the cost-effectiveness of the Xpert MTB/RIF assay for TB diagnosis: a decision analysis. PloS One 2013;8:e82786.
14. Girosi F, Olmsted SS, Keeler E, et al. Developing and interpreting models to improve diagnostics in developing countries. Nature 2006;444(suppl 1):3-8.
15. Olmsted SS, Petkin Derose K, Beighley C. Determining access to care and user requirements for diagnostic tests in developing countries. Working paper. Nature 2006; S1:3-8, supportive material.
16. Wells WA, Boehme CC, Cobelens FG, et al. Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect Dis 2013;13:449-58.